Article info
PDFOvarian Cancer
Prognostic Impact of Prechemotherapy Serum Levels of HER2, CA125, and HE4 in Ovarian Cancer Patients
- Address correspondence and reprint requests to Karina Dahl Steffensen, MD, PhD, Department of Oncology, Vejle Hospital, Kabbeltoft 25, DK-7100 Vejle, Denmark. E-mail: Karina.Dahl.Steffensen{at}slb.regionsyddanmark.dk.
Citation
Prognostic Impact of Prechemotherapy Serum Levels of HER2, CA125, and HE4 in Ovarian Cancer Patients
Publication history
- Received December 21, 2010
- First published August 1, 2011.
Online issue publication
February 26, 2019
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright © 2011 by IGCS and ESGO